EGFR Tyrosine Kinase Inhibitor Combined With Concurrent or Sequential Chemotherapy for Advanced Lung Cancer Patients of Gradual Progression After First-line EGFR-TKI Therapy: a Randomized Controlled Study
Phase: PHASE2
Conditions: Lung Adenocarcinoma, EGFR Activating Mutation
Sponsor: Shanghai Chest Hospital

- 1 - 
EGFR tyrosine kinase inhibitor combined with synchronous or 
sequential chemotherapy for advanced NSCLC patients of gradual 
progression after first-line EGFR-TKI therapy: a randomized 
controlled study 
 
Principal Investigators：Tianqing Chu 
Clinical Trial Participants：Chest Hospital Affiliated to Shanghai Jiaotong 
University 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

- 2 - 
Table of Contents 
Abstract .......................................................................................................................................3 
1 Backgroud ................................................................................................................................5 
2 Study purpose ...........................................................................................................................7 
3 Study participants .....................................................................................................................9 
3.1 Inclusion criteria ...............................................................................................................9 
3.2 Exclusion criteria ............................................................................................................10 
3.3 Stop criteria .....................................................................................................................12 
3.3 Standard for discontinued testing ....................................................................................13 
4 Study design ...........................................................................................................................14 
4.1 Sample size estimates......................................................................................................14 
4.2 Method of randomization ................................................................................................14 
4.3 Supportive care guidelines ..............................................................................................15 
4.4 Dosing modification........................................................................................................15 
5 Observation items ..................................................................................................................17 
5.1 Before enrollment ...........................................................................................................17 
5.2 During of therapy ............................................................................................................17 
5.3 After disease progression ................................................................................................18 
5.4 Sample collection ............................................................................................................18 
6 Test method for EGFR mutations ..........................................................................................19 
7 Efficacy evaluation ................................................................................................................19 
8 Safety assessments .................................................................................................................21 
8.1 Adverse events ................................................................................................................21 
8.2 Time period for collecttion of adverse events .................................................................21 
8.3 Judgement of relationship between drug and adverse events .........................................21 
8.4 Serious adverse events ....................................................................................................22 
8.5 Reporting of serious adverse events ...............................................................................22 
9 Follow-up ...............................................................................................................................23 
10 Statistical analysis ................................................................................................................24 
11 References ............................................................................................................................25 
 
 
 
 

- 3 - 
Abstract 
Research topic 
EGFR tyrosine kinase inhibitor combined with synchronous or 
sequential chemotherapy for advanced NSCLC patients of gradual 
progression after first-line EGFR-TKI therapy: a randomized 
controlled study 
Purpose 
The purpose of this study is to investigate whether concurrent use 
of EGFR-TKI and chemotherapy can achieve better response than 
sequential use of EGFR-TKI and chemotherapy in advanced 
EGFR-activating 
NSCLC 
patients 
who 
occurred 
gradual 
progression after first-line EGFR-TKI treatment and to investigate 
genetic alteration and peripheral blood immune cell phenotype 
change during the EGFR-TKI therapy. 
Endpoints 
Primary endpoints: progression-free survival (PFS) 
Secondary endpoints: objective response rate (ORR), disease 
control rate (DCR), overall survival (OS), safety index 
Study design 
Single center, randomized, open-label 
Enrollment 
Patients who occurred gradual progression on first-line 
EGFR-TKI therapy are randomly assigned 1: 1 to synchronous 
therapy group or sequential therapy group. 
Inclusion criteria (Details see page 9 to 10)： 
1) Signed informed consent for the study 
2) Histologically or cytologically stage IIIB or IV adenocarcinoma  
3) Sensitive EGFR mutations (19 del, 21L858R) 

- 4 - 
4) With measurable lesions 
5) Patients achieved the gradual progression after first-line EGFR-TKI therapy 
6) Able to comply with study and follow-up procedures 
7) Age >=18 years, ECOG PS: 0~2, estimated survival duration more than 3 
months； 
Exclusion criteria (Details see page 10 to 12) ： 
1) Evidence of non-adenocarcinoma histology 
2) EGFR wild-type patients, or patients with rare EGFR mutations or complex 
EGFR mutations  
3) Symptomatic or untreated brain metastases 
4) Unstable systemic disease 
5) History of other unstable diseases. 
6) Pregnancy or lactation 
 
 
 
 
 
 
 
 
 

- 5 - 
1 Background 
Lung cancer is the most common cause of cancer-related deaths worldwide[1], and 
approximately 85 to 90% of all lung cancer cases are non-small cell lung cancer 
(NSCLC). More than 70% of lung cancer cases are diagnosed at an advanced stage, 
which means that surgery is not an option for most of these patients. EGFR mutations 
are one of the most common lung cancer-driven genes. In particular, as many as 
51.4% of EGFR mutations occur in Asian patients with adenocarcinoma.[2]It has been 
absolutely confirmed that compared with the traditional chemotherapy treatment, 
EGFR tyrosine-kinase inhibitors (TKIs) can significantly improve the objective 
response rate (ORR) and progression free survival(PFS), and become a standard 
first-line treatment for NSCLC patients with EGFR mutation-positive.[3-11]  
  However, it is unavoidable that almost all patients develop acquired resistance to 
EGFR-TKI with a median progression-free survival time of only 8 to 13 months[3-11]. 
The concept of  acquired resistance for EGFR-TKI was defined by Jackman[12] 
according to Response Evaluation Criteria in Solid Tumors (RECIST) or the World 
Health Organization definition of progression[13]. However，we can see that the 
RECIST is increasingly showing the limitation of EGFR-TKI evaluation in clinical 
work. Wu et al demonstrated clinical modes of EGFR-TKI failure could favor 
strategies for subsequent treatment and predicting a survival benefit in advanced 
NSCLC. For those patients with gradual progression in clinical practice, continuation 
of EGFR-TKI would be an optimal treatment strategy after failure. Also several 
studies[14-16] have reported continuation of EGFR-TKI may delay second-line therapy.  

- 6 - 
Besides a second mutation, such as T790M and c-MET amplification is related to the 
failure of EGFR-TKI therapy, nearly 40% of acquired resistance mechanism is remain 
unknown. Thus, the way that prolong the duration from gradual progression to 
eventual failure seems to be optimal strategy. 
Although there is no evidence whether additional chemotherapy can further delay 
acquired EGFR-TKI resistance for gradual progression patients. We once found[17] 
first line treatment with chemotherapy (pemetrexed plus cisplatin) combined with 
EGFR-TKI could provide better survival benefits for patients with lung 
adenocarcinoma harboring sensitive EGFR mutations. Therefore, this study would 
investigate for patients with EGFR-TKI gradual progression, whether chemotherapy 
combined with TKI could provide more benefit than first continuing EGFR-TKI and 
then chemotherapy alone.  
In order to further understand the mechanism of drug resistance, this study would 
conduct some exploratory analyses by using mass spectrometry technology to detect 
genetic alteration and peripheral blood immune cell phenotype change during the 
EGFR-TKI therapy. 
 
 
 
 
 

- 7 - 
2 Study purpose  
To directly compare different strategy (concurrent use of EGFR-TKI and 
chemotherapy or sequential use of EGFR-TKI and chemotherapy) in terms of efficacy 
and safety in advanced EGFR-activating NSCLC patients who occurred gradual 
progression after first-line EGFR-TKI treatment and to investigate genetic alteration 
and peripheral blood immune cell phenotype change during the EGFR-TKI therapy. 
 
2.1 Primary objective 
   PFS, PFS is defined as the time from the date of randomization to the first date of 
disease progression or death from any cause. For patients who don’t have objective 
progressive disease or don’t know whether or not have died at the cut-off date, PFS is 
censored at the date of the last objective progression-free disease assessment.  
   For the sequential therapy group, PFS is defined as PFS1(from gradual 
progression to discontinue EGFR-TKI) plus PFS2(chemotherapy alone). 
 
2.2 Second objective 
1)ORR, ORR is defined as the percentage of patients with complete remission and 
partial remission and maintaining the number of evaluable patients over 4 weeks. 
 
2)DCR, DCR is defined as the percentage of patients with complete remission, partial 
remission, and disease stabilization and maintaining the number of evaluable patients over 4 
weeks. 
 

- 8 - 
3)OS, OS is measured from the date of randomization to the date of death. For each 
patient who was not known to have died as of the data inclusion cut-off date for a 
particular analysis, OS was censored for that analysis at the date of last prior contact. 
 
4)Safety index (National Cancer Institute Common Terminology Criteria for 
adverse events, version 4·0.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

- 9 - 
3 Study participants 
3.1 Inclusion criteria  
1) Patients had to voluntarily join the study and give written informed consent for the 
study 
2) Histologically documented, unresectable, inoperable, locally advanced, recurrent or 
metastatic stage IIIB or IV adenocarcinoma. 
3) A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology) 
4) Sensitive EGFR mutations (19del, 21L858R) 
5) At least one unidimensionally measurable lesion meeting Response Evaluation 
Criteria in Solid Tumours (RECIST) criteria.  
6) Patients achieved the gradual progression after first-line EGFR-TKI therapy. 
The criteria of gradual progression[18]: 
(1) disease control≥6 months with EGFR-TKI treatment; 
(2) compared with the previous assessment，no significant increment of tumor 
burden and progressive involvement of non-target lesions with a score ≤2; 
(3) symptom scored≤1. 
7) Patients did not receive any chemotherapy previously.  
8) Able to comply with study and follow-up procedures 
9) Age >=18 years, ECOG PS: 0~2, estimated survival duration more than 3 
months； 
10) Major organ function 
（1） For regular test results（no blood transfusion within 14 days）： 

- 10 - 
a) Hemoglobin（HB）≥90g/L； 
b) Absolute neutrophils count（ANC）≥1.5×109/L； 
c) Blood platelets（PLT）≥80×109/L 
（2） Biochemical tests results defined as follows： 
a) Total bilirubin（TBIL）≤1.5 times the upper limit of normal (ULN) ； 
b) Alanine aminotransferase（ALT）and aspartate aminotransgerase 
AST≤2.5ULN，liver metastases，if any，ALT 和AST≤5ULN； 
c) Creatinine（Cr）≤1.5ULN or Creatinine Clearance rate (CCr)≥60 
ml/min； 
（3）Doppler ultrasound assessment：left ventricular ejection fraction (LVEF) 
≥the lower limit of normal value (50%). 
 
3.2 Exclusion criteria： 
1) Other types of non-small cell lung cancer except adenocarcinoma and Small cell 
lung cancer（including patients with mixed small cell lung cancer and non-small 
cell lung cancer）； 
2) Evidence of other types of non-small cell lung cancer except adenocarcinoma, 
small cell, carcinoid, or mixed small cell/non-small cell histology 
3) EGFR wild-type patients, or patients with rare EGFR mutations or complex EGFR 
mutations  
4) Patients achieved the dramatic progression after first-line EGFR-TKI therapy. 
The criteria of dramatic progression[18]: 

- 11 - 
(1) disease control lasting ≥3 months with EGFR-TKI treatment; 
(2) compared with the previous assessment, rapid progression of multiple target 
lesions, or progressive involvement of non-target lesions with a score >2; 
(3) symptom scored 2. 
5) Patients achieved the local progression after first-line EGFR-TKI therapy. 
The criteria of local progression[18]: 
(1) disease control lasting ≥3 months with EGFR-TKI treatment; 
(2) PD due to solitary extracranial lesion or limitation in intracranial lesions 
(covered by a radiation field); 
(3) symptom scored≤1. 
6) Previously (within 5 years) or presently suffering from other malignancies 
7) A in situ，non-melanoma skin cancers and superficial bladder cancer [Ta 
(noninvasive carcinoma)，Tis (carcinoma in situ) and T1 (invasion into lamina 
propria)]； 
8) [19]Unstable 
systemic 
disease, 
including 
active 
infection, 
uncontrolled 
hypertension, unstable angina, congestive heart failure, or myocardial infarction 
within 6 months prior to Day 1, or serious cardiac arrhythmia requiring 
medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or 
paroxysmal supraventricular tachycardia, are eligible) 
9) History of other diseases, metabolic dysfunction, physical examination finding, or 
clinical laboratory finding giving reasonable suspicion of a disease or condition 
that contraindicates the use of an investigational drug or that might affect the 

- 12 - 
interpretation of the results of the study or render the patient at high risk from 
treatment complications 
10) Gastrointestinal tract disease resulting in an inability to take oral medication or a 
requirement for intravenous (IV) alimentation, or prior surgical procedures 
affecting absorption 
11) Pregnancy or lactation 
 
3.3 Stop criteria (The reasons for withdrawal will be specified and recorded.) 
1)  Disease progression or death from any cause 
2) In case patient is allergic to pemetrexed, cisplatin or icotinib 
3) The patient is noncompliant with study procedures. 
4) Unacceptable toxicity (The investigator decides that whether the patient should 
be withdrawn from study treatment. If this decision is made because of toxicity, a 
serious AE (SAE), or a clinically significant laboratory value, the study drug is to 
be discontinued, and appropriate measures are to be taken.) 
5) The patient has had 2 (Day 1) dose reductions and experiences an AE that would 
cause a third dose reduction. 
6) The patient becomes pregnant or fails to use adequate birth control (for those 
patients who are able to conceive). 
7) According to the informed consent form, the subjects have the right to withdraw 
from the trial. Subjects who do not accept treatment or re-examinations will be 
withdrawn.  

- 13 - 
3.4 Standards for discontinued testing 
The following standards for discontinued testing will be applied:  
1) a serious safety problem occurs 
2) major mistakes are found in the designed clinical protocol during the trial  
3) The sponsor of this trial requests discontinued testing because of a lack of funds or 
poor management. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

- 14 - 
4 Study design 
4.1 Sample size 
The sample size was set at 120 patients in total on the basis of several assumptions: a 
median PFS of 5 months with chemotherapy alone beyond first-line EGFR TKI 
therapy, 8.5 months for chemotherapy combined with EGFR TKI; and 80% power to 
detect a hazard ratio (HR) of 0.50 with an overall a level of 5%. 
4.2 Randomization 
Patients were allocated in a 1:1 ratio using minimization software. Randomization 
was stratified by EGFR mutation status. 
 
 
 
 
 
 
 
 
Synchronized group 
Continued using the initial EGFR-TKI (icotinib (125 mg/time, 3 times/day every day))  
combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) 
and repeat every four weeks for up to six cycles and then continue to receive 
pemetrexed combined with EGFR-TKI every four weeks. 
Patients with gradual progression after 
first-line EGFR-TKI therapy: 
1:1 randomized to treatment 
Synchronized group 
Sequential group 

- 15 - 
 
Sequential group 
Continued using the initial EGFR-TKI (icotinib (125 mg/time, 3 times/day every day)) 
alone until the investigator judged that continuation was adiaphorous, and switched to 
Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat 
every four weeks for up to six cycles and then continue to receive pemetrexed every 
four weeks. 
 
4.3 Supportive Care Guidelines 
If the patient experiences nausea or vomiting despite the above-mentioned 
pre-medications, appropriate anti-nausea and anti-emetic therapy may be administered 
at the discretion of the investigator. 
The use of erythrocyte colony stimulating factors (erythropoeitin or darbapoeitin) is 
allowed.  
Other medication other than that described above, which is considered necessary for 
the subject safety and well being, may be given at the discretion of the investigator. 
 
4.4 Dosing delays/dose modifications 
Assuming that there is a normal proportion of granulocytes, the chemotherapy will be 
allowed to continue if the WBCC is within the range of 3.0 to 4.0 × 109/l. If the 
WBCC falls within the range of 2.0 to 3.0 × 109/l, chemotherapy will be stopped until 
the WBCC increases to 3.0 × 109/l, or above. Granulocyte colony-stimulating factor 
will be used for supportive treatment if WBCC decreases to 2.0 × 109/l or below. The 

- 16 - 
doses of chemotherapy drugs will be decreased by 25% in the next cycle if IV degree 
toxicity (including fever-induced neutropenia syndrome) emerges. Chemotherapy will 
be stopped in advance in cases of disease progression, or unacceptable AEs, even the 
patient may not finish the chemotherapy plan. 
 
If a patient experiences a grade 3 or higher unacceptable toxicity, which the 
investigator considers to be associated with EGFR-TKI, dosing will be interrupted, 
and relevant supportive treatment will be administered.  
 
Treatment may be delayed for up to 49 days to allow a patient sufficient time for 
recovery from study drug-related toxicity. Patients should be removed from study if 
treatment is delayed more than 3 weeks due to toxicity or if more than two dose 
reductions are necessary. 
 
Any patient who requires a dose reduction will continue to receive the reduced dose 
for the remainder of the study. Any patient who has had 2 dose reductions and who 
experiences a toxicity that would cause a third dose reduction must be discontinued 
from study therapy.  
 
 
 
 

- 17 - 
5 Observation 
5.1 Before enrollment (before the start of treatment, the patients should complete the 
following tests) 
1. History & physical examination, including measurement of height, weight, vital 
signs and performance status 
2. Blood chemistry: bilirubin, alkaline phosphatase, ALT, AST, BUN, creatinine, 
total protein, albumin, calcium, phosphorus, electrolytes, glucose 
3. CT scan of chest, The abdomen ultrasonic. 
4. Electrocardiogram 
5. Blood CEA, Cyfra21-1, NSE, SCC, Ca125 test 
6. MRI or CT scan of brain 
7. Radionuclide bone scan (if PET scan available [within 4 weeks], bone scan not 
necessary) 
 
5.2 Duration of Therapy 
1. History & physical examination, including measurement of height, weight, vital 
signs and performance status (Before every cycle). 
2. Blood chemistry: bilirubin, alkaline phosphatase, ALT, AST, BUN, creatinine, 
total protein, albumin, calcium, phosphorus, electrolytes, glucose (Before every 
cycle). 
3. CT scan of chest, the abdomen ultrasonic (Before every two cycles).  
4. Blood CEA, Cyfra21-1, NSE, SCC, Ca125 test (Before every cycle).  

- 18 - 
5. Electrocardiogram (Before every cycle). 
6. MRI or CT scan of brain every 3 months.  
7. Radionuclide bone scan every 6 months. 
 
5.3 After disease progression  
All of the Patients who arrived the criteria of disease progression will be suggested to 
detect the most common resistant mutation-EGFR T790M mutation by biopsy or 
blood sample, but whether to conduct the EGFR mutation analysis is determined by 
the patient. 
Biopsy sample will be used to detect the EGFR T790M mutation by amplification 
refractory mutation system(ARMS), and blood sample will be detected by digital 
droplet polymerase chain reaction (ddPCR) technology. 
 
5.4 Sample collection (use to exploratory analysis) 
1. ctDNA- to detect immune cell phenotype and gene state: collect 8ml peripheral 
blood (collecting by tube with EDTA-K2 anticoagulant) at prior treatment, one month 
and every 2 months later. 
2. Immune cell phenotype- to detect immune cell phenotype: collect 5ml peripheral 
blood (collecting by tube with heparin sodium) at prior treatment, one month and 
every 2 months later. 
 
 

- 19 - 
6 Test method for EGFR mutations 
The highly sensitive method termed Amplification Refractory Mutation System 
(ARMS) was used to detect mutations in the EGFR gene according to the 
manufacturer’s protocol of the DxS EGFR mutation test kit. 
 
 
7 Efficacy evaluation (RECIST guideline 1.1) 
Complete Response (CR): Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to < 
10mm 
 
Partial Response (PR): At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters. 
 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of 
one or more new lesions is also considered progression).  
 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 

- 20 - 
study 
 
Special notes on the assessment of target lesions and non-target lesions  
Target lesions 
Non-target lesions 
New lesions 
Overall 
response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all evaluated 
No 
PR 
SD 
Non-PD or not all evaluated 
No 
SD 
Not all evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
CR = complete 
response, 
PR = partial 
response, 
SD = stable 
disease, 
PD = progressive disease, and NE = invaluable. 
 
 
 
 
 

- 21 - 
8 Safety assessments 
 
8.1 Adverse events 
Adverse events are development of an undesirable medical condition following or 
exposure to treatment agents. An undesirable medical condition includes symptoms, 
or abnormal laboratory findings. The adverse events were graded according to 
National Cancer Institute Common Terminology Criteria for adverse events, version 
4.0.  
 
8.2 Time period for collection of adverse events 
Adverse events will be collected from the start of therapy throughout the treatment 
period and including the safety follow-up period. The follow-up period is defined as 
28 days after study treatment is discontinued. All the AEs after starting the trial should 
be followed until satisfactory resolution, or the primary researcher should determine if 
the AEs have stabilized.  
 
8.3 Judgement of relationship between drug and adverse events 
The determination of whether an adverse event is related to a medical treatment is 
categorized as one of five associations. The definition of “related” is that there is a 
reasonable possibility that the drug caused the adverse experience.   
Definite - The adverse event is clearly related to the medical treatment.   
Probable - The adverse event is likely related to the medical treatment.   
Possible - The adverse event may be related to the medical treatment.   

- 22 - 
Unlikely - The adverse event is doubtfully related to the medical treatment.   
Unrelated - The adverse event is clearly NOT related to the medical treatment.   
 
8.4 Serious adverse event 
A serious adverse event (experience) or reaction is any untoward medical occurrence 
that at any dose results in:  
1. death 
2. life-threatening 
3. requires inpatient hospitalization 
4. prolongation of existing hospitalization 
5. persistent or significant disability/incapacity 
6. a congenital anomaly/birth defect 
 
Serious adverse events will be captured from first dose of any study treatment to 30 
days after last dose of the study treatment, unless deemed as related to the study 
treatment by the Investigator.  
If serious AEs occur, corresponding countermeasures will be conducted by 
researchers according to the drug-induced symptoms to ensure patient safety.  
 
8.5 Reporting serious adverse events 
Adverse events classified as serious require expeditious handling and reporting to 
comply with regulatory requirements. Any serious adverse event or death must be 
reported independent of the circumstances or suspected cause if it occurs or comes to 

- 23 - 
the attention of the investigator at any time during the study through 30 days after the 
last administration of study drug. Any serious adverse event occurring beyond 30 days 
after last administration of study drug must be promptly reported if a causal 
relationship to study drug is suspected.  
 
 
9 Follow up  
Post-Treatment:  The follow-up schedule is the same for both arms of the study.  
Follow up visits are to be conducted every 16 weeks (+/-30 days) after the start of 
therapy. Patient will be monitored for progression until death.   
Suggested disease assessments in response to symptoms: 
 If the patient has new symptoms of bone or back pain, a bone scan should be 
done 
 If the patient has symptoms of abdominal pain or if the physician notes 
jaundice, hepatomegaly, or an elevation in the liver function tests, a CT scan 
of the abdomen should be done. 
 If the patient exhibits a change in mental or neurologic status, A CT scan or 
MRI of the brain should be done. 
 
 
 
 

- 24 - 
10 Statistical analysis 
The data will be collected and analyzed according to the intention-to-treat principle. 
Standard statistical techniques will be used to describe characteristics of patients in 
both groups.  
PFS and OS will be analyzed by using the Kaplan-Meier method and performed the 
multivariate analysis using the Cox proportional hazards model, included the 
following covariates: gender, age, smoking history, EGFR mutations status (deletions 
in exon 19 vs. L858R), tumor stage and previous response to TKI. ORR and DCR will 
be analyzed by chi-square statistics or Fisher’s exact tests. A significance level of 5% 
will be used throughout the analysis. All statistical analyses will be conducted using 
the SPSS software, version 23 (IBM, Armonk, NY). 
 
 
 
 
 
 
 
 
 
 

- 25 - 
11 Reference 
[1] Mok  TS, Wu  Y-L, Thongprasert  S, Yang  C-H, Chu  D-T, Saijo  N, et al. 
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma[J]. New England 
Journal of Medicine. 2009,361(10):947-57. 
[2] Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, et al. A 
Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients 
with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology 
(PIONEER)[J]. Journal of Thoracic Oncology. 2014,9(2):154-62. 
[3] Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong 
V, et al. Biomarker analyses and final overall survival results from a phase III, 
randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in 
clinically selected patients with advanced non-small-cell lung cancer in Asia 
(IPASS)[J]. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2011,29(21):2866-74. 
[4] Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus 
chemotherapy 
as 
first-line 
treatment 
for 
patients 
with 
advanced 
EGFR 
mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a 
multicentre, open-label, randomised, phase 3 study[J]. The Lancet Oncology. 
2011,12(8):735-42. 
[5] Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. 
Erlotinib versus standard chemotherapy as first-line treatment for European patients 
with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a 

- 26 - 
multicentre, open-label, randomised phase 3 trial[J]. The Lancet Oncology. 
2012,13(3):239-46. 
[6] Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib 
versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive 
non-small-cell lung cancer: analyses from the phase III, randomized, open-label, 
ENSURE study[J]. Annals of oncology : official journal of the European Society for 
Medical Oncology. 2015,26(9):1883-9. 
[7] Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, et al. First-line icotinib versus 
cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced 
EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, 
randomized study[J]. Annals of oncology : official journal of the European Society for 
Medical Oncology. 2017,28(10):2443-50. 
[8] Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: 
first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers 
with adenocarcinoma of the lung[J]. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2012,30(10):1122-8. 
[9] Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, et al. Gefitinib 
Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor 
Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib 
(IMPRESS): Overall Survival and Biomarker Analyses[J]. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 
2017,35(36):4027-34. 

- 27 - 
[10] Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. 
Updated overall survival results from a randomized phase III trial comparing gefitinib 
with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive 
EGFR gene mutations (NEJ002)[J]. Annals of oncology : official journal of the 
European Society for Medical Oncology. 2013,24(1):54-9. 
[11] Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer 
harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open 
label, randomised phase 3 trial[J]. The Lancet Oncology. 2010,11(2):121-8. 
[12] Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical 
definition of acquired resistance to epidermal growth factor receptor tyrosine kinase 
inhibitors in non-small-cell lung cancer[J]. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2010,28(2):357-60. 
[13] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. 
New response evaluation criteria in solid tumours: revised RECIST guideline (version 
1.1)[J]. European journal of cancer (Oxford, England : 1990). 2009,45(2):228-47. 
[14] Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-Line 
Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors 
Progression in Asian Patients With Epidermal Growth Factor Receptor 
Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study[J]. JAMA 
oncology. 2016,2(3):305-12. 
[15] Nishino K, Imamura F, Morita S, Mori M, Komuta K, Kijima T, et al. A 

- 28 - 
retrospective analysis of 335 Japanese lung cancer patients who responded to initial 
gefitinib treatment[J]. Lung cancer. 2013,82(2):299-304. 
[16] Soria J-C, Wu Y-L, Nakagawa K, Kim S-W, Yang J-J, Ahn M-J, et al. Gefitinib 
plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive 
non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a 
phase 3 randomised trial[J]. The Lancet Oncology. 2015,16(8):990-8. 
[17] Han B, Jin B, Chu T, Niu Y, Dong Y, Xu J, et al. Combination of chemotherapy 
and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma 
and sensitive EGFR mutations: A randomized controlled trial[J]. International journal 
of cancer. 2017,141(6):1249-56. 
[18] Yang J-J, Chen H-J, Yan H-H, Zhang X-C, Zhou Q, Su J, et al. Clinical modes of 
EGFR tyrosine kinase inhibitor failure and subsequent management in advanced 
non-small cell lung cancer[J]. Lung cancer. 2013,79(1):33-9. 
[19] Li L, Wang H, Li C, Wang Z, Zhang P, Yan X. Transformation to small-cell 
carcinoma as an acquired resistance mechanism to AZD9291: A case report[J]. 
Oncotarget. 2017,8(11):18609-14.